Xenogeneic immunization with human tyrosine hydroxylase DNA vaccines suppresses growth of established neuroblastoma.
Neuroblastoma (NB) is a challenging malignancy of the sympathetic nervous tissue characterized by a very poor prognosis. One important marker for NB is the expression of tyrosine hydroxylase (TH), the first-step enzyme of catecholamine biosynthesis. We could show stable and high TH gene expression in 67 NB samples independent of the clinical stage. Based on this observation, we addressed the question of whether xenogeneic TH DNA vaccination is effective in inducing an anti-NB immune response. For this purpose, we generated three DNA vaccines based on pCMV-F3Ub and pBUD-CE4.1 plasmids encoding for human (h)THcDNA (A), hTH minigene (B), and hTHcDNA in combination with the proinflammatory cytokine interleukin 12 (C), and tested prophylactic and therapeutic efficacy to suppress primary tumor growth and spontaneous metastasis. Here we report that xenogeneic TH DNA vaccination was effective in eradicating established primary tumors and inhibiting metastasis. Interestingly, this effect could not be enhanced by adding the Th1 cytokine interleukin 12. However, increased IFN-gamma production and NB cytotoxicity of effector cells harvested from vaccinated mice suggested the participation of tumor-specific CTLs in the immune response. The depletion of CD8(+)T cells completely abrogated the hTH vaccine-mediated anti-NB immune response. Furthermore, rechallenging of surviving mice resulted in reduced primary tumor growth, indicating the induction of a memory immune response. In conclusion, xenogeneic immunization with TH-derived DNA vaccines is effective against NB, and may open a new venue for a novel and effective immunotherapeutic strategy against this challenging childhood tumor.
Huebener
Nicole
N
Department of Pediatrics, Allergy Center Charité, Charité-University Medicine Berlin, Berlin, Germany.
Fest
Stefan
S
Hilt
Kerstin
K
Schramm
Alexander
A
Eggert
Angelika
A
Durmus
Tahir
T
Woehler
Anja
A
Stermann
Alexander
A
Bleeke
Matthias
M
Baykan
Bianca
B
Weixler
Silke
S
Gaedicke
Gerhard
G
Lode
Holger N
HN
D000818:Animals; D015478:Antigens, Heterophile / Q000008:administration & dosage*; D016466:CHO Cells; D006224:Cricetinae; D003412:Cricetulus; D005260:Female; D006801:Humans; D007114:Immunization; D018664:Interleukin-12 / Q000378:metabolism; D051379:Mice; D009447:Neuroblastoma / Q000276:immunology / Q000473:pathology / Q000628:therapy*; D014446:Tyrosine 3-Monooxygenase / Q000235:genetics* / Q000378:metabolism; D019444:Vaccines, DNA / Q000008:administration & dosage* / Q000276:immunology
D015478:Antigens, Heterophile; D019444:Vaccines, DNA; D018664:Interleukin-12; D014446:Tyrosine 3-Monooxygenase